Navigation Links
New Lung Association Study Shows $142 Billion Benefit of Converting to Zero-Emission Vehicles by 2030
Date:3/20/2008

The 'Road to a Cleaner Future' Study Finds Zero-Emission Vehicles Can Avoid Health Costs From Premature Deaths and Illnesses, and Reduce Global Warming

Impacts

SACRAMENTO, Calif., March 20 /PRNewswire/ -- According to a study sponsored by the American Lung Association of California, $142 billion in human health and global warming reduction benefits would result from converting the entire California motor vehicle fleet from gasoline vehicles to zero-emission vehicle (ZEV) technologies in the 2010-2030 timeframe, or $96 billion more than relying on the lowest emitting gasoline technologies. The $142 billion figure includes $38 billion in benefits to society from reduced global warming emissions.

The study, conducted by TIAX LLC, a consulting firm specializing in transportation and alternative fuels research, also found that California can avoid at least $2.2 billion per year in health costs from reduction of dangerous particulate matter by converting the motor vehicle fleet to ZEVs instead of relying on the lowest emitting gasoline technologies. This reduction in particulates means that California would annually avoid 300 cases of premature death, over 260 cases of chronic bronchitis, over 7,000 asthma attacks and more than 18,000 cases of upper and lower respiratory symptoms by moving to ZEV technology.

"Maintaining our momentum toward cleaner cars will save billions in health costs, and save lives," said Tony Gerber, MD, an American Lung Association of California volunteer. "Now is not the time for the California Air Resources Board (ARB) to weaken the state's key program that leads to cleaner vehicle technology, and cleaner air." Dr. Gerber is a pulmonary specialist and assistant professor at the University of California, San Francisco.

American Lung Association of California Senior Policy Director Bonnie Holmes-Gen will testify on the results of the study when the ARB holds a hearing on Thursday, M
'/>"/>

SOURCE American Lung Association of California
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Randy Jackson and the American Heart Association Educate Raleigh Area Residents About the Connection Between Type 2 Diabetes and Cardiovascular Disease
2. American Heart Association Meeting Report
3. Capital BlueCross Receives Prestigious Brand Excellence Award From The Blue Cross & Blue Shield Association
4. AUDIO from Medialink and the Anxiety Disorders Association of America: Treat It, Dont Repeat It: Break Free from OCD
5. Pennsylvania Dental Association Urges Members to Use New ADA Educational Material
6. Statement of Bernadette Toomey, President and Chief Executive Officer, American Lung Association
7. The Attention Deficit Disorder Association and The HealthCentral Network Form Alliance to Develop New Online Resources for Adult ADHD
8. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
9. SEIU: Thousands of Ohio Nurses and Other Healthcare Employees Denied a Voice at Work After Vicious Union-Busting Campaign by the California Nurses Association
10. Drinking Water Association Discusses Pharmaceuticals in Water
11. California Small Business Association Condemns California Nurses Associations Decision to Call Prolonged Strike at Hospitals Throughout Northern California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ncephalitis this year has been confirmed in a nine... health officials the boy is seriously ill and has... John Fontaine. Middleborough was included in the...rial spraying on August eighth to kill the virus c...
... hospital in the capital were restored and most ho...he cessation of the strike by resident doctors. Th...University, Indraprastha University, called off th...e reservation bill to the Parliament’s Standing Co...
...d the Northern Territory Government’s decision to ...couraged other jurisdictions to follow suit and he...y disease. The NT’s decision came after the Federa...s Advisory Committee (PBAC) concluded that it woul...
...gland Journal of Medicine states that skin infecti...// . Gregory Moran the lead author of the study, ...ys, “MRSA, has become the leading cause of such in...oms.” He further mentioning that, it now accounts ...
Other Medicine News:Health News:MRSA Fast Becoming The Leading Cause Of Skin Infections 2
(Date:9/3/2008)...ber is National Vascular Disease Awareness Month, ...fusion Pharmaceuticals,LLC, a clinical-stage drug-...the treatment of unmet medical needs, announced to...e I/II clinical trial of its lead drug,candidate t...ed NCT00725881,on the clinicaltrials.gov Website, ...
(Date:9/3/2008)... Md., Sept. 3 /- Panacea Pharmaceutic...ent Number 7,413,737 covering,antibodies against h...), a,proprietary human cancer biomarker and therap...ollaboration with the Massachusetts Institute of,T...de rights to this patent,for development of human ...
(Date:9/3/2008)...Company to Discuss Phase 3 Plans with FDA, PRINCE...ics, Inc.,announced today that it successfully co... of the company,s new, innovative low-dose, once-w...rs to by its internal product,code AG-200-15. The ...t its,primary endpoint of ovulation suppression, c...
(Date:9/3/2008)...rial Reconfirms Strong Evidence Pycnogenol(R) Lowe...ect on Joints Following Cessation ...3 /- According to the Center for,Dise... type of arthritis,is on the rise. A new study pu...arch, reveals Pycnogenol(R), bark extract from the...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 1Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 2Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 3Stimuvax 28R 29 Phase II data highlight three year survival results for patients with non small cell lung cancer 376 4Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 1Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 2Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 3Cardicas C Port 28R 29 Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed Chest Heart Bypass Surgeries 371 4R P Simmons Family Foundation Pledges 242 Million for New Childrens Hospital of Pittsburgh of UPMC Campus 530 1R P Simmons Family Foundation Pledges 242 Million for New Childrens Hospital of Pittsburgh of UPMC Campus 530 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 1Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 369 3
...Lymphoma Reported,Today at ASCO Annual Meeting, PH...thKline plc,announced today long-term efficacy dat...e of frontline treatment with the BEXXAR(R),Therap...momab) in,76 patients with newly diagnosed advance...gimen was found to induce durable clinical,and mol...
...e/ -- (SEND2PRESS,NEWSWIRE) -- Epeius Biotechnolog... a historic landmark in medical oncology and a,def...gene therapy.,The first clinical report of its kin...ue of the International Journal of,Oncology, Vol.3...res of tumor destruction observed in chemo-resista...
Other Medicine Technology:8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 2News from the Battlefield of Metastatic Cancer: Epeius,Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G),from the Stone of Chemistry and Physics 3
Tank Blotting System. Designed for Western, Northern, or Southern Blotting. Transfer up to three gels with dimensions as large as 15cm x 21.5cm. Includes and internal cooling base for temperature
... proven electrophoretic transfer apparatus incorpo...ltimate in field uniformity. Its design allows for... when coupled with a low voltage power source such...ts/cm. The result is exceptionally rapid and exact...
...lot cell, a component of Bio-Rad's modular mini el...resis Systems), provides rapid, high-quality blott...ransfers two 7.5 x 10 cm gels in just 1 hour. Cool... absorbs heat generated during transfers. The Mini...
Includes PowerPac 200 power supply. Flexibility for a Range of Parameters. Quantitative Transfers. Native Enzyme, High Intensity, or Overnight Transfers. Faster, Higher-Efficiency Transfers via Pl
Medicine Products: